Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.

Neil A O'BrienMartina S J McDermottDylan ConklinTong LuoRaul AyalaSuruchi SalgarKevin ChauEmmanuelle DiTomasoNaveen BabbarFaye SuAlex GaitherSara A HurvitzRonald LinnartzKristine RoseSamit HirawatDennis J Slamon

Published in: Breast cancer research : BCR (2020)

These data support the clinical investigation of p110α-selective inhibitors of PI3K, such as alpelisib, in patients with ER+/HER2- breast cancer who have progressed on CDK4/6:ER-based therapies. Our data also support the investigation of PI3K:CDK4/6:ER triple combination therapy to prevent the onset of resistance to the combination of endocrine therapy plus CDK4/6 inhibition.

Keyphrases

cell cycle
combination therapy
positive breast cancer
estrogen receptor
endoplasmic reticulum
breast cancer cells
cell proliferation
electronic health record
big data
stem cells
cell therapy
cancer therapy
drug delivery
data analysis
bone marrow